<p>Squarepoint Ops LLC 在最近向证券交易委员会（SEC）提交的 13F 表格中表示，在第二季度将其在 Arcutis Biotherapeutics, Inc.（NASDAQ:ARQT - 免费报告）中的持股增加了 169.2%。该公司在本季度购买了额外的 105,487 股后，持有该公司 167,814 股股票。Squarepoint Ops LLC 在最近一个季度末持有的 Arcutis Biotherapeutics 的股份约占 0.14%，价值 2,353,000 美元。</p>
<ul>
<li>3 个生物技术催化剂带来重大机会</li>
</ul>
<p>其他几家机构投资者也对该公司的持股进行了调整。Allostery Investments LP 在第一季度收购了 Arcutis Biotherapeutics 的新股份，价值约为 117,000 美元。PNC Financial Services Group Inc. 在第二季度将其在 Arcutis Biotherapeutics 的持股增加了 10.2%。PNC Financial Services Group Inc. 目前持有该公司 8,828 股股票，价值 124,000 美元，此前在上个季度购买了额外的 820 股。Atlas Wealth LLC 在第二季度收购了 Arcutis Biotherapeutics 的新股份，价值 138,000 美元。Quantbot Technologies LP 在第二季度购买了 Arcutis Biotherapeutics 的新股份，价值 145,000 美元。最后，Russell Investments Group Ltd. 在第二季度将其在 Arcutis Biotherapeutics 的持股增加了 4,562.5%。Russell Investments Group Ltd. 目前持有该公司 11,190 股股票，价值 157,000 美元，此前在此期间购买了额外的 10,950 股。</p>
<h2>Arcutis Biotherapeutics 的内部买卖</h2>
<p>在相关消息中，内部人士 Larry Todd Edwards 于 11 月 6 日星期四出售了 29,131 股 Arcutis Biotherapeutics 的股票。该股票以平均价格 25.16 美元出售，总价值为 732,935.96 美元。交易完成后，内部人士持有该公司 150,193 股股票，价值约为 3,778,855.88 美元。此次交易使其持股减少了 16.24%。该交易已在向证券交易委员会提交的文件中披露，您可以通过此链接访问。此外，内部人士 Patrick Burnett 于 11 月 6 日星期四出售了 17,250 股该公司的股票。该股票以平均价格 24.18 美元出售，总价值为 417,105.00 美元。交易完成后，内部人士在公司中持有 98,325 股，价值约为 2,377,498.50 美元。此次交易使其持股减少了 14.93%。有关此次出售的更多细节可在官方 SEC 披露中找到。内部人士在过去九十天内出售了价值 8,638,027 美元的 339,229 股公司股票。公司内部人士持有公司股票的 9.40%。</p>
<h2>Arcutis Biotherapeutics 股价下跌 0.7%</h2>
<p>NASDAQ ARQT 的股票在星期四开盘价为 28.34 美元。该公司的市值为 34.7 亿美元，市盈率为 -78.72，贝塔值为 1.69。该公司的 50 日简单移动平均线为 25.75 美元，200 日简单移动平均线为 19.15 美元。Arcutis Biotherapeutics, Inc. 的 52 周低点为 11.13 美元，52 周高点为 31.77 美元。该公司的债务与股本比率为 0.68，速动比率为 3.28，流动比率为 3.50。</p>
<p>Arcutis Biotherapeutics（NASDAQ:ARQT - 获取免费报告）最近于 10 月 28 日星期二发布了季度财报。该公司报告本季度每股收益为 0.06 美元，超出市场共识预期的 -0.10 美元，超出幅度为 0.16 美元。该公司本季度的收入为 9922 万美元，而分析师预期为 8669 万美元。Arcutis Biotherapeutics 的净利润率为 -13.94%，股本回报率为 -29.69%。研究分析师平均预测 Arcutis Biotherapeutics, Inc. 本财年每股收益将为 -1.33 美元。</p>
<h2>分析师评级上调与下调</h2>
<p>几位研究分析师最近对该公司进行了评估。Needham &amp; Company LLC 将 Arcutis Biotherapeutics 的目标股价从 22.00 美元上调至 30.00 美元，并在 10 月 28 日的研究报告中给予该公司 &#34;买入&#34; 评级。Zacks Research 在 10 月 29 日的报告中将 Arcutis Biotherapeutics 的评级从 &#34;持有&#34; 上调至 &#34;强力买入&#34;。瑞穗证券在 11 月 28 日的研究报告中将 Arcutis Biotherapeutics 的目标股价从 32.00 美元上调至 37.00 美元，并给予该股票 &#34;跑赢大盘&#34; 的评级。Wall Street Zen 在一份研究报告中将 Arcutis Biotherapeutics 的评级从 &#34;买入&#34; 上调至 &#34;强力买入&#34;。最后，Weiss Ratings 在周一的研究报告中重申了对 Arcutis Biotherapeutics 股票的 &#34;卖出（d-）&#34; 评级。一位分析师对该股票给予了强力买入评级，六位分析师给予了买入评级，一位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，该公司目前的平均评级为 &#34;适度买入&#34;，共识目标股价为 29.00 美元。</p>
<p><strong>查看我们对 ARQT 的最新分析</strong></p>
<h2>关于 Arcutis Biotherapeutics</h2>
<p>（免费报告）</p>
<p>Arcutis Biotherapeutics, Inc. 是一家生物制药公司，专注于开发和商业化皮肤病治疗药物。其主要产品候选药物是 ARQ-151，一种已完成针对斑块型银屑病和特应性皮炎的 III 期临床试验的外用罗氟米特乳膏。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 Arcutis Biotherapeutics</li>
<li>天然气价格持续上涨，这些股票将受益</li>
<li>在上涨 35% 后，分析师关注铜巨头 Freeport 的更多上涨空间</li>
<li>3 个股票代码引领了迷因股的复兴</li>
<li>为什么 SpaceX 的 IPO 可能成为 GOOGL 股票的重大催化剂</li>
<li>如何寻找被低估的股票</li>
<li>Upwork 能否维持其复苏？看涨和看跌的理由</li>
</ul>
<p><strong>想看看其他对 ARQT 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Arcutis Biotherapeutics, Inc.（NASDAQ:ARQT - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJRVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJRVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Arcutis Biotherapeutics 吗？</h2>
<p>在考虑 Arcutis Biotherapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Arcutis Biotherapeutics 并不在名单上。</p>
<p>虽然 Arcutis Biotherapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ARQT

<p>Squarepoint Ops LLC 在第二季度将其在 Arcutis Biotherapeutics 的持股增加了 169.2%，目前持有 167,814 股，价值 235 万美元。内部人士最近出售了价值 864 万美元的股票。Arcutis 股票开盘价为 28.34 美元，市值为 34.7 亿美元。分析师上调了评级，目标价格范围在 30 美元到 37 美元之间。该公司报告第三季度每股收益为 0.06 美元，超出预期</p>

<p>Squarepoint Ops LLC grew its position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 169.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 167,814 shares of the company's stock after buying an additional 105,487 shares during the quarter. Squarepoint Ops LLC owned approximately 0.14% of Arcutis Biotherapeutics worth $2,353,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Squarepoint Ops LLC 在最近向证券交易委员会（SEC）提交的 13F 表格中表示，在第二季度将其在 Arcutis Biotherapeutics, Inc.（NASDAQ:ARQT - 免费报告）中的持股增加了 169.2%。该公司在本季度购买了额外的 105,487 股后，持有该公司 167,814 股股票。Squarepoint Ops LLC 在最近一个季度末持有的 Arcutis Biotherapeutics 的股份约占 0.14%，价值 2,353,000 美元。</p>
</div><ul>
<li>3 Biotech Catalysts Present Major Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>3 个生物技术催化剂带来重大机会</li>
</ul>
</div><p>Several other institutional investors have also made changes to their positions in the company. Allostery Investments LP acquired a new stake in shares of Arcutis Biotherapeutics during the first quarter valued at approximately $117,000. PNC Financial Services Group Inc. grew its position in Arcutis Biotherapeutics by 10.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 8,828 shares of the company's stock worth $124,000 after purchasing an additional 820 shares in the last quarter. Atlas Wealth LLC acquired a new stake in Arcutis Biotherapeutics during the 2nd quarter valued at $138,000. Quantbot Technologies LP purchased a new stake in shares of Arcutis Biotherapeutics in the second quarter valued at $145,000. Finally, Russell Investments Group Ltd. boosted its position in shares of Arcutis Biotherapeutics by 4,562.5% in the second quarter. Russell Investments Group Ltd. now owns 11,190 shares of the company's stock worth $157,000 after buying an additional 10,950 shares during the period.</p>
<div class="lb-trans"><p>其他几家机构投资者也对该公司的持股进行了调整。Allostery Investments LP 在第一季度收购了 Arcutis Biotherapeutics 的新股份，价值约为 117,000 美元。PNC Financial Services Group Inc. 在第二季度将其在 Arcutis Biotherapeutics 的持股增加了 10.2%。PNC Financial Services Group Inc. 目前持有该公司 8,828 股股票，价值 124,000 美元，此前在上个季度购买了额外的 820 股。Atlas Wealth LLC 在第二季度收购了 Arcutis Biotherapeutics 的新股份，价值 138,000 美元。Quantbot Technologies LP 在第二季度购买了 Arcutis Biotherapeutics 的新股份，价值 145,000 美元。最后，Russell Investments Group Ltd. 在第二季度将其在 Arcutis Biotherapeutics 的持股增加了 4,562.5%。Russell Investments Group Ltd. 目前持有该公司 11,190 股股票，价值 157,000 美元，此前在此期间购买了额外的 10,950 股。</p>
</div><h2>Insider Buying and Selling at Arcutis Biotherapeutics</h2>
<div class="lb-trans"><h2>Arcutis Biotherapeutics 的内部买卖</h2>
</div><p>In related news, insider Larry Todd Edwards sold 29,131 shares of Arcutis Biotherapeutics stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $25.16, for a total value of $732,935.96. Following the completion of the sale, the insider owned 150,193 shares of the company's stock, valued at approximately $3,778,855.88. The trade was a 16.24% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. Also, insider Patrick Burnett sold 17,250 shares of the firm's stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $24.18, for a total value of $417,105.00. Following the transaction, the insider owned 98,325 shares in the company, valued at approximately $2,377,498.50. This trade represents a 14.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 339,229 shares of company stock worth $8,638,027 in the last ninety days. Company insiders own 9.40% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Larry Todd Edwards 于 11 月 6 日星期四出售了 29,131 股 Arcutis Biotherapeutics 的股票。该股票以平均价格 25.16 美元出售，总价值为 732,935.96 美元。交易完成后，内部人士持有该公司 150,193 股股票，价值约为 3,778,855.88 美元。此次交易使其持股减少了 16.24%。该交易已在向证券交易委员会提交的文件中披露，您可以通过此链接访问。此外，内部人士 Patrick Burnett 于 11 月 6 日星期四出售了 17,250 股该公司的股票。该股票以平均价格 24.18 美元出售，总价值为 417,105.00 美元。交易完成后，内部人士在公司中持有 98,325 股，价值约为 2,377,498.50 美元。此次交易使其持股减少了 14.93%。有关此次出售的更多细节可在官方 SEC 披露中找到。内部人士在过去九十天内出售了价值 8,638,027 美元的 339,229 股公司股票。公司内部人士持有公司股票的 9.40%。</p>
</div><h2>Arcutis Biotherapeutics Trading Down 0.7%</h2>
<div class="lb-trans"><h2>Arcutis Biotherapeutics 股价下跌 0.7%</h2>
</div><p>Shares of NASDAQ ARQT opened at $28.34 on Thursday. The stock has a market cap of $3.47 billion, a price-to-earnings ratio of -78.72 and a beta of 1.69. The business has a 50 day simple moving average of $25.75 and a 200 day simple moving average of $19.15. Arcutis Biotherapeutics, Inc. has a 52 week low of $11.13 and a 52 week high of $31.77. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.28 and a current ratio of 3.50.</p>
<div class="lb-trans"><p>NASDAQ ARQT 的股票在星期四开盘价为 28.34 美元。该公司的市值为 34.7 亿美元，市盈率为 -78.72，贝塔值为 1.69。该公司的 50 日简单移动平均线为 25.75 美元，200 日简单移动平均线为 19.15 美元。Arcutis Biotherapeutics, Inc. 的 52 周低点为 11.13 美元，52 周高点为 31.77 美元。该公司的债务与股本比率为 0.68，速动比率为 3.28，流动比率为 3.50。</p>
</div><p>Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last issued its quarterly earnings data on Tuesday, October 28th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.16. The firm had revenue of $99.22 million for the quarter, compared to analyst estimates of $86.69 million. Arcutis Biotherapeutics had a negative net margin of 13.94% and a negative return on equity of 29.69%. On average, research analysts predict that Arcutis Biotherapeutics, Inc. will post -1.33 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Arcutis Biotherapeutics（NASDAQ:ARQT - 获取免费报告）最近于 10 月 28 日星期二发布了季度财报。该公司报告本季度每股收益为 0.06 美元，超出市场共识预期的 -0.10 美元，超出幅度为 0.16 美元。该公司本季度的收入为 9922 万美元，而分析师预期为 8669 万美元。Arcutis Biotherapeutics 的净利润率为 -13.94%，股本回报率为 -29.69%。研究分析师平均预测 Arcutis Biotherapeutics, Inc. 本财年每股收益将为 -1.33 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><p>Several research analysts recently weighed in on the company. Needham &amp; Company LLC upped their price target on Arcutis Biotherapeutics from $22.00 to $30.00 and gave the company a &#34;buy&#34; rating in a research report on Tuesday, October 28th. Zacks Research upgraded Arcutis Biotherapeutics from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a report on Wednesday, October 29th. Mizuho increased their price target on shares of Arcutis Biotherapeutics from $32.00 to $37.00 and gave the stock an &#34;outperform&#34; rating in a research report on Friday, November 28th. Wall Street Zen raised shares of Arcutis Biotherapeutics from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Sunday. Finally, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Arcutis Biotherapeutics in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $29.00.</p>
<div class="lb-trans"><p>几位研究分析师最近对该公司进行了评估。Needham &amp; Company LLC 将 Arcutis Biotherapeutics 的目标股价从 22.00 美元上调至 30.00 美元，并在 10 月 28 日的研究报告中给予该公司 &#34;买入&#34; 评级。Zacks Research 在 10 月 29 日的报告中将 Arcutis Biotherapeutics 的评级从 &#34;持有&#34; 上调至 &#34;强力买入&#34;。瑞穗证券在 11 月 28 日的研究报告中将 Arcutis Biotherapeutics 的目标股价从 32.00 美元上调至 37.00 美元，并给予该股票 &#34;跑赢大盘&#34; 的评级。Wall Street Zen 在一份研究报告中将 Arcutis Biotherapeutics 的评级从 &#34;买入&#34; 上调至 &#34;强力买入&#34;。最后，Weiss Ratings 在周一的研究报告中重申了对 Arcutis Biotherapeutics 股票的 &#34;卖出（d-）&#34; 评级。一位分析师对该股票给予了强力买入评级，六位分析师给予了买入评级，一位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，该公司目前的平均评级为 &#34;适度买入&#34;，共识目标股价为 29.00 美元。</p>
</div><p><strong>View Our Latest Analysis on ARQT</strong></p>
<div class="lb-trans"><p><strong>查看我们对 ARQT 的最新分析</strong></p>
</div><h2>About Arcutis Biotherapeutics</h2>
<div class="lb-trans"><h2>关于 Arcutis Biotherapeutics</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.</p>
<div class="lb-trans"><p>Arcutis Biotherapeutics, Inc. 是一家生物制药公司，专注于开发和商业化皮肤病治疗药物。其主要产品候选药物是 ARQ-151，一种已完成针对斑块型银屑病和特应性皮炎的 III 期临床试验的外用罗氟米特乳膏。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Arcutis Biotherapeutics</li>
<li>Natural Gas Prices Continue To Rally, These Stocks Should Benefit</li>
<li>Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport</li>
<li>3 Tickers Leading a Meme Stock Revival</li>
<li>Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock</li>
<li>How to Find Undervalued Stocks</li>
<li>Can Upwork Maintain Its Comeback? Reasons to Be Bullish and Bearish</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Arcutis Biotherapeutics</li>
<li>天然气价格持续上涨，这些股票将受益</li>
<li>在上涨 35% 后，分析师关注铜巨头 Freeport 的更多上涨空间</li>
<li>3 个股票代码引领了迷因股的复兴</li>
<li>为什么 SpaceX 的 IPO 可能成为 GOOGL 股票的重大催化剂</li>
<li>如何寻找被低估的股票</li>
<li>Upwork 能否维持其复苏？看涨和看跌的理由</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ARQT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 ARQT 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Arcutis Biotherapeutics, Inc.（NASDAQ:ARQT - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJRVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=ARQT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Arcutis Biotherapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Arcutis Biotherapeutics 吗？</h2>
</div><p>Before you consider Arcutis Biotherapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Arcutis Biotherapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcutis Biotherapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Arcutis Biotherapeutics 并不在名单上。</p>
</div><p>While Arcutis Biotherapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Arcutis Biotherapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Squarepoint Ops LLC 持有价值 235 万美元的 Arcutis Biotherapeutics, Inc. $ARQT 股份